![](https://immunomart.com/wp-content/uploads/2024/05/HY-19712.gif)
Download Files:
LJH685
SKU
HY-19712-10 mg
Category Reference compound
Tags Apoptosis;MAPK/ERK Pathway, Apoptosis;Ribosomal S6 Kinase (RSK), Cancer
$120 – $1,320
Products Details
Product Description
– LJH685 is a potent, ATP-competitive and selective RSK inhibitor, inhibits RSK1, 2, and 3 biochemical activities with IC50s of 6, 5, 4 nM, respectively[1].
Web ID
– HY-19712
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C22H21F2N3O
References
– [1]My-My Huynh, et al. RSK2: a promising therapeutic target for the treatment of triple-negative breast cancer. Expert Opin Ther Targets. 2020 Jan;24(1):1-5.|[2]Aronchik I, et al. Novel potent and selective inhibitors of p90 ribosomal S6 kinase reveal the heterogeneity of RSK function in MAPK-driven cancers. Mol Cancer Res. 2014 May;12(5):803-12.|[3]Davies AH, et al. Inhibition of RSK with the novel small-molecule inhibitor LJI308 overcomes chemoresistance by eliminating cancer stem cells. Oncotarget. 2015 Aug 21;6(24):20570-7.|[4]Jain R, et al. Discovery of Potent and Selective RSK Inhibitors as Biological Probes. J Med Chem. 2015 Sep 10;58(17):6766-83.
CAS Number
– 1627710-50-2
Molecular Weight
– 381.42
Compound Purity
– 99.99
SMILES
– OC1=C(F)C=C(C2=C(C3=CC=C(N4CCN(C)CC4)C=C3)C=CN=C2)C=C1F
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– DMSO : ≥ 31 mg/mL
Target
– Apoptosis;Ribosomal S6 Kinase (RSK)
Isoform
– RSK1
Pathway
– Apoptosis;MAPK/ERK Pathway
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.